Beamr video compression achieves up to 50% improvement for AVs
DEERFIELD, Ill. - Walgreens Specialty Pharmacy, a division of the $10.38 billion market cap healthcare giant, has expanded its limited distribution drug (LDD) network to include 265 products, according to a company press release issued Tuesday. The company’s stock has shown strong momentum with a 28.62% gain year-to-date, according to InvestingPro data.
Limited distribution drugs are specialty medications available only through select specialty pharmacies chosen by manufacturers. These medications typically involve complex regimens, high costs, or require special handling.
As an independent specialty pharmacy not directly affiliated with a pharmacy benefit manager, Walgreens can collaborate with various payers, pharmaceutical companies, and healthcare providers. The company maintains a FAIR financial health score according to InvestingPro analysis, with revenue reaching $154.58 billion in the last twelve months and growing at 6.22%.
Recent additions to Walgreens’ LDD network in 2025 include Gilead’s Yeztugo (lenacapavir), described as the first FDA-approved twice-yearly option for HIV prevention; Galderma’s Nemluvio (nemolizumab) for moderate-to-severe atopic dermatitis and prurigo nodularis; and Shorla Oncology’s Imkeldi (imatinib) for certain forms of leukemia and other cancers.
"As the limited distribution drug network continues to grow, our specialty pharmacy teams across the country are equipped to support manufacturers in getting their medications to patients who need it most," said Tracey James, chief operating officer of Walgreens Specialty Pharmacy.
The company noted that specialty pharmacy represents one of the fastest-growing segments in healthcare, with specialty drugs now comprising approximately 75% of new drugs in development.
Walgreens Specialty Pharmacy employs teams of specialty pharmacists, nurses, patient advocates, and insurance specialists trained to support patients with complex health conditions. The pharmacy holds several national accreditations and provides services to nearly 300 million covered lives nationwide.
In other recent news, Walgreens Boots Alliance has been at the center of several significant developments. Shareholders have approved an acquisition by Sycamore Partners, with an overwhelming 96% of votes in favor. This transaction will provide Walgreens shareholders $11.45 per share in cash, along with a potential additional $3.00 per share from the future monetization of interests in VillageMD and related businesses. Concurrently, Blazing Star Merger Sub, Inc. has extended the tender offer expiration date for Walgreens’ outstanding notes to August 21, 2025, aligning with the anticipated merger closing. Pricing details for these tender offers have been announced, covering notes with maturity dates from 2025 to 2050, with substantial portions tendered by the early deadline. Walgreens has also announced a temporary blackout period for its employee retirement savings plans due to the pending merger. Each share of Walgreens common stock will be exchanged for cash and a divested asset proceed right. Additionally, Evercore ISI has reiterated its In Line rating for Walgreens, maintaining a price target of $11.45. The firm’s analysis noted that Walgreens’ quarterly results were consistent with previous estimates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.